A directory of where to buy chemicals in the USA, including: distributors, industrial manufacturers, bulk supplies and wholesalers of raw ingredients & finished goods.
Search for products or services, then visit the suppliers website for prices or more information.
| Product | Description | |
|---|---|---|
| GSK620 | GSK620 is a potent and orally active pan-BD2 inhibitor with excellent broad selectivity, developability and in vivo oral pharmacokinetics. GSK620 is highly selective for the BET-BD2 family of proteins, with >200-fold selectivity over all other bromodomains. GSK620 shows an anti-inflammatory phenotype in human whole blood[1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 2088410-46-0. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-137892. |  |
| GSK621 | ?98% (HPLC). Group: Fluorescence/luminescence spectroscopy. |  |
| GSK621 | GSK621 is a specific AMPK activator, with IC50 values of 13-30 ?M for AML cells. GSK621 induces autophagy and apoptosis. GSK621 induces eiF2? phosphorylation-a hallmark of UPR activation[1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 1346607-05-3. Pack Sizes: 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-100548. | |
| GSK621 | GSK621 is an activator of AMP-activated protein kinase (AMPK). GSK621 induces autophagy and apoptosis. GSK621 induces eiF2α phosphorylation-a hallmark of UPR activation. Synonyms: GSK-621; GSK 621. Grades: 98%. CAS No. 1346607-05-3. Molecular formula: C26H20ClN3O5. Mole weight: 489.91. |  |
| GSK-626616 | GSK-626616 is a potent, orally bioavailable inhibitor of DYRK3 (IC50=0.7 nM). GSK-626616 inhibits other members of the DYRK family (e.g., DYRK1A and DYRK2) with similar potency, which is a potential therapy for the treatment of anemia[1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 1025821-33-3. Pack Sizes: 10 mM * 1 mL; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-105309. | |
| GSK-626616 | GSK-626616 is a YAK3/DYRK3 kinase inhibitor. It is a chemoprotective agent for the potential treatment of chemotherapy-induced anaemia. Uses: Gsk-626616 is a chemoprotective agent for the potential treatment of chemotherapy-induced anaemia. Synonyms: GSK-626616; GSK 626616; GSK626616; (5Z)-2-(2,6-Dichloroanilino)-5-(quinoxalin-6-ylmethylidene)-1,3-thiazolone;GSK626616;(5Z)-2-(2,6-dichloroanilino)-5-(quinoxalin-6-ylmethylidene)-1,3-thiazol-4-one. Grades: >98 %. CAS No. 1025821-33-3. Molecular formula: C18H10Cl2N4OS. Mole weight: 401.26. | |
| GSK650394 | GSK650394 is a competitive inhibitor that quantitatively blocks the effect of androgens on LNCaP cell growth. Synonyms: GSK650394; GSK-650394; GSK 650394. Grades: 0.98. CAS No. 890842-28-1. Molecular formula: C25H22N2O2. Mole weight: 382.45. | |
| GSK 650394 | GSK 650394 is a novel SGK inhibitor with IC 50 of 62 nM and 103 nM for SGK1 and SGK2 in the SPA assay respectively. GSK 650394 also inhibits influenza virus replication. Uses: Scientific research. Group: Signaling pathways. CAS No. 890842-28-1. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg. Product ID: HY-15192. | |
| GSK 650394 | GSK 650394 Inhibitor. Uses: Scientific use. Product Category: T2622. CAS No. 890842-28-1. |  |
| GSK-650394 | ?98% (HPLC). Group: Fluorescence/luminescence spectroscopy. | |
| GSK682753A | GSK682753A is a selective and highly potent inverse agonist of the epstein-barr virus-induced receptor 2 (EBI2) with an IC50 of 53.6 nM. Uses: Scientific research. Group: Signaling pathways. CAS No. 1334294-76-6. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-101192. | |
| GSK6853 | GSK6853 is a potent (pKd 9.5), soluble, cell active (20 nM), and highly selective inhibitor of the BRPF1 bromodomain with greater than 1600-fold selectivity over all other bromodomains tested. Synonyms: N-[1,3-dimethyl-6-[(2R)-2-methylpiperazin-1-yl]-2-oxobenzimidazol-5-yl]-2-methoxybenzamide; GSK6853; GSK-6853; GSK-6853. Grades: >98%. CAS No. 1910124-24-1. Molecular formula: C22H27N5O3. Mole weight: 409.49. | |
| GSK6853 | ?98% (HPLC). Group: Fluorescence/luminescence spectroscopy. | |
| GSK690693 | ?98% (HPLC). Group: Fluorescence/luminescence spectroscopy. | |
| GSK-690693 | GSK-690693 is an ATP-competitive pan-Akt inhibitor with IC50s of 2 nM, 13 nM, 9 nM for Akt1, Akt2 and Akt3, respectively. GSK-690693 is also an AMPK inhibitor, affects Unc-51-like autophagy activating kinase 1 (ULK1) activity and robustly inhibits STING-dependent IRF3 activation[1][2][3]. Uses: Scientific research. Group: Signaling pathways. CAS No. 937174-76-0. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-10249. | |
| GSK-690693 | GSK690693 is a pan-AKT kinase inhibitor, is also an aminofurazan-derived inhibitor of Akt kinases with potential antineoplastic activity. Pan-AKT kinase inhibitor GSK-690693 binds to and inhibits Akt kinases 1, 2, and 3, which may result in the inhibition of protein phosphorylation events downstream from Akt kinases in the PI3K/Akt signaling pathway, and, subsequently, the inhibition of tumor cell proliferation and the induction of tumor cell apoptosis. In addition, this agent may inhibit other protein kinases including protein kinase C (PKC) and protein kinase A (PKA). As serine/threonine protein kinases which are involved in a number of biological processes, AKT kinases promote cell survival by inhibiting apoptosis and are required for glucose transport. Synonyms: GSK-690693; GSK690693. CAS No. 937174-76-0. Molecular formula: C21H27N7O3. Mole weight: 425.48418. | |
| GSK717 | GSK717 is a potent, selective NOD2 (nucleotide-binding oligomerization domain 2) inhibitor. GSK717 inhibits muramyl dipeptide (MDP)-induced NOD2-mediated signaling, with an IC50 of 400 nM for MDP-stimulated IL-8 secretion in HEK293/hNOD2 cells[1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 1595278-21-9. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-136555. | |
| GSK-7186 | GSK-7186 is a novel inhibitor of HIV integrase that is used for the treatment of Non-cross-resistant HIV infection. Uses: The treatment of non-cross-resistant hiv infection. Synonyms: GSK7186; GSK 7186. | |
| GSK7227 | GSK7227 is a novel class of PPARdelta partial agonists. It shows potent partial agonism of the PPARdelta target genes CPT1a and PDK4 in skeletal muscle cells. Synonyms: GSK-7227; GSK7227; GSK 7227; 2-[[3-(5-Methoxy-4-methylindol-1-yl)sulfonylbenzoyl]amino]-5-methylbenzoic acid;GSK-7227;Benzoic acid, 2-((3-((5-methoxy-4-methyl-1H-indol-1-yl)sulfonyl)benzoyl)amino)-5-methyl-. Grades: >98%. CAS No. 1067214-81-6. Molecular formula: C25H22N2O6S. Mole weight: 478.52. | |
| GSK761 | GSK761 is a selective inhibitor of speckled 140 kDa (SP140) with an IC50 value of 77.79 nM. GSK761 reduces monocyte-to-inflammatory macrophage differentiation and lipopolysaccharide (LPS)-induced inflammatory activation. GSK761 induces the production of CD206+ regulatory macrophages by inhibiting SP140[1]. Uses: Scientific research. Group: Signaling pathways. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-148591. | |
| GSK778 | GSK778 (iBET-BD1) is a potent and selective BD1 bromodomain inhibitor of the BET proteins, with IC50s of 75 nM (BRD2 BD1), 41 nM (BRD3 BD1), 41 nM (BRD4 BD1), and 143 nM (BRDT BD1), respectively. GSK778 phenocopies the effects of pan-BET inhibitors in cancer models[1]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: iBET-BD1. CAS No. 2451862-42-1. Pack Sizes: 10 mM * 1 mL; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-136570. | |
| GSK 789472 hydrochloride | GSK 789472 hydrochloride. Group: Biochemicals. Grades: Purified. CAS No. 1257326-24-1. Pack Sizes: 10mg, 50mg. US Biological Life Sciences. |  Worldwide |
| GSK 789472 hydrochloride | GSK 789472 hydrochloride is a selective dopamine D3 receptor antagonist and D2 partial agonist (pEC50 values are <5.5 and 8.3, respectively). GSK 789472 exhibits selectivity against the D4 receptor in both agonist and antagonist assays. Synonyms: GSK 789472 hydrochloride; GSK-789472 hydrochloride; GSK789472 hydrochloride; 4,5-Dihydro-1-phenyl-3-(2-piperidinyl)methylimidazol-2(1H)-one hydrochloride; 1-phenyl-3-(piperidin-2-ylmethyl)imidazolidin-2-one hydrochloride. Grades: ≥99% by HPLC. CAS No. 1257326-24-1. Molecular formula: C15H21N3O.HCl. Mole weight: 295.81. | |
| GSK-7975A | This active molecular is a calcium release-activated calcium modulator (ORAI1) inhibitor. GSK-7975A inhibited toxin-induced activation of ORAI1 and/or activation of Ca(2+) currents after Ca(2+) release in mouse and human pancreatic acinar cells. GSK-7975A may be used for the treatment of pancreatitis in the future. Uses: Pancreatitis. Synonyms: GSK-7975A; GSK 7975A; GSK7975A; GSK-7975; GSK 7975; GSK7975. SCHEMBL705705; AOB4124; CPYTVBALBFSXSH-UHFFFAOYSA-N; 2, 6-difluoro-N-[1-[[4-hydroxy-2- (trifluoromethyl) phenyl]methyl]pyrazol-3-yl]benzamide. Grades: 98%. CAS No. 1253186-56-9. Molecular formula: C18H12F5N3O2. Mole weight: 397.31. | |
| GSK-7975A | GSK-7975A is a potent and orally available CRAC channel inhibitor. Uses: Scientific research. Group: Signaling pathways. CAS No. 1253186-56-9. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-12507. | |
| GSK805 | GSK805 is an orally active and CNS penetrant ROR?t inhibitor. GSK805 inhibits ROR? and Th17 cells differentiation with pIC50 values of 8.4 and >8.2. GSK805 inhibits the function of Th17 cells. GSK805 can be used for the research of immunity[1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 1426802-50-7. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-12776. | |
| GSK805 | GSK805 Inhibitor. Uses: Scientific use. Product Category: T7388. CAS No. 1426802-50-7. | |
| GSK837149 | GSK837149 is a selective inhibitor of human fatty acid synthase (FAS; Ki value 30 nM) that acts via suppressing the β-ketoacyl reductase activity of the enzyme. Synonyms: GSK837149A; GSK-837149-A; GSK 837149 A; 1,3-bis[4-[(4-methylpyrimidin-2-yl)sulfamoyl]phenyl]urea. Grades: 99%. CAS No. 13616-29-0. Molecular formula: C23H22N8O5S2. Mole weight: 554.6. | |
| GSK837149A | ?98% (HPLC), solid. Group: Fluorescence/luminescence spectroscopy. | |
| GSK840 | GSK840 (GSK'840) is a receptor-interacting protein kinase 3 (RIP3 or RIPK3) inhibitor, which binds RIP3 kinase domain with an IC50 of 0.9 nM, and inhibits kinase activity with an IC50 of 0.3 nM[1]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: GSK'840. CAS No. 2361146-30-5. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-104021. | |
| GSK-843 | GSK-843 (GSK'843) is a receptor-interacting protein kinase 3 (RIP3 or RIPK3) inhibitor, which binds RIP3 kinase domain with an IC50 of 8.6 nM, and inhibits kinase activity with an IC50 of 6.5 nM. GSK-843 can be used for the research of inflammation[1][2]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: GSK'843. CAS No. 1601496-05-2. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-125402. | |
| GSK-8573 | GSK-8573 is an inactive control of GSK-2801, which is a potent inhibitor of BAZ2A and BAZ2B bromodomains. Synonyms: GSK8573; GSK 8573; GSK-8573; 1-[1-(3-Methoxyphenyl)-7-propoxyindolizin-3-yl]ethanone. CAS No. 1693766-04-9. Molecular formula: C20H21NO3. Mole weight: 323.392. | |
| GSK8612 | GSK8612 is a highly selective and potent Tank-binding Kinase-1 (TBK1) inhibitor, with a pIC50 of 6.8 for recombinant TBK1[1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 2361659-62-1. Pack Sizes: 10 mM * 1 mL; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-111941. | |
| GSK864 | GSK864 is a cell penetrant, selective allosteric inhibitor of isocitrate dehydrogenase 1 (IDH1) mutant with IC50 values of 8.8, 15.2 and 16.6 nM for IDH1 mutants R132C, R132H, and R132G, respectively. Synonyms: (7S)-1-[(4-fluorophenyl)methyl]-3-N-(4-methoxy-3,5-dimethylphenyl)-7-methyl-5-(1H-pyrrole-2-carbonyl)-4,6-dihydropyrazolo[4,3-c]pyridine-3,7-dicarboxamide; GSK 864; GSK-864. CAS No. 1816331-66-4. Molecular formula: C30H31FN6O4. Mole weight: 558.6. | |
| GSK864 | ?98% (HPLC). Group: Fluorescence/luminescence spectroscopy. | |
| GSK-872 | GSK-872 is a RIPK3 inhibitor, which binds RIP3 kinase domain with an IC50 of 1.8 nM, and inhibits kinase activity with an IC50 of 1.3 nM. GSK-872 decreases the RIPK3-mediated necroptosis and subsequent cytoplasmic translocation and expression of HMGB1, as well as ameliorates brain edema and neurological deficits in early brain injury[1][2][3]. Uses: Scientific research. Group: Signaling pathways. CAS No. 1346546-69-7. Pack Sizes: 10 mM * 1 mL; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-101872. | |
| GSK'872 | GSK'872 is a RIPK3 inhibitor, which binds RIP3 kinase domain with high affinity (IC50=1.8 nM), and is approximately >1,000-fold selective over 300 kinases in a fluorescence polarization assay at a concentration of 1 μM. Besides, GSK'872 inhibits kinase activity (IC50=1.3 nM). Synonyms: GSK872; GSK-872; GSK 872; N-(6-propan-2-ylsulfonylquinolin-4-yl)-1,3-benzothiazol-5-amine. CAS No. 1346546-69-7. Molecular formula: C19H17N3O2S2. Mole weight: 383.49. | |
| GSK-872 hydrochloride | GSK-872 hydrochloride is a RIPK3 inhibitor, which binds RIP3 kinase domain with an IC50 of 1.8 nM, and inhibits kinase activity with an IC50 of 1.3 nM. GSK-872 hydrochloride decreases the RIPK3-mediated necroptosis and subsequent cytoplasmic translocation and expression of HMGB1, as well as ameliorates brain edema and neurological deficits in early brain injury[1][2][3]. Uses: Scientific research. Group: Signaling pathways. CAS No. 2703752-81-0. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-101872A. | |
| GSK894490A | GSK894490A is a non-peptide ghrelin receptor agonist. It crosses the blood/brain barrier and elicit pro-cognitive effects in recognition and spatial learning and memory tests. It may be used as a potential drug target for therapeutic approaches to treat diseases affecting cognition. Uses: Gsk894490a may be used as a potential drug target for therapeutic approaches to treat diseases affecting cognition. Synonyms: Benzenesulfonamide, N-(5-((3R,5S)-3,5-dimethyl-1-piperazinyl)-2-methoxyphenyl)-4-(5-methyl-2-furanyl)-, hydrochloride (1:1), rel-;N-[5-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-2-methoxyphenyl]-4-(5-methylfuran-2-yl)benzenesulfonamide hydrochloride;GSK-894490A. Grades: >98 %. CAS No. 1012035-06-1. Molecular formula: C24H30ClN3O4S. Mole weight: 492.03. | |
| GSK 9027 | GSK 9027 is a glucocorticoid receptor agonist (pIC50 = 8) inhibiting production of the proinflammatory mediator IL-6 in vivo. GSK 9027 is used for the treatment of acute and chronic inflammatory conditions. Synonyms: GSK 9027; GSK9027; GSK-9027; N-[4-[1- (4-Fluorophenyl) -1H-indazol-5-yl-3- (trifluoromethyl) phenyl]benzenesulfonamide. Grades: ≥98% by HPLC. CAS No. 1229096-88-1. Molecular formula: C27H19F4N3O2S. Mole weight: 525.52. | |
| GSK923295 | GSK923295. Group: Biochemicals. Alternative Names: GSK-923295, 3-chloro-N- [ (2S) -1- [ [2- (dimethylamino) acetyl]amino]-3- [4- [8- [ (1S) -1hydroxyethyl]imidazo [1, 2-a]pyridin-2-yl]phenyl]propan-2-yl]-4-propan-2-yloxybenzamide. CAS No. 1088965-37-0. Pack Sizes: 5mg, 50mg. Molecular Formula: C32 H38 ClN 5O4 , Molecular Weight: 592.1. US Biological Life Sciences. | Worldwide |
| GSK-923295 | GSK-923295 is a special, allosteric inhibitor of centromere-associated protein-E (CENP-E) kinesin motor ATPase activity, with Ki of 3.2±0.2 nM and 1.6± 0.1 nM for human and canine, respectively. Uses: Scientific research. Group: Signaling pathways. CAS No. 1088965-37-0. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-10299. | |
| GSK-923295 | GSK-923295 is a novel antimitotic inhibitor of centromere-associated protein E (CENP-E) with potential anticancer activity. GSK-923295 demonstrated significant antitumor activity against solid tumor models, inducing CRs in Ewing sarcoma, rhabdoid, and rhabdomyosarcoma xenografts. Clinical study showed that GSK-923295 had dose-proportional pharmacokinetics and a low number of grade 3 or 4 adverse events. The observed incidence of myelosuppression and neuropathy was low. Further investigations may provide a more complete understanding of the potential for GSK-923295 as an antiproliferative agent. Synonyms: GSK923295; GSK 923295; GSK-923295; GSK-923295A; GSK923295A; GSK 923295A. Grades: 98%. CAS No. 1088965-37-0. Molecular formula: C32H38ClN5O4. Mole weight: 592.14. | |
| GSK9311 | ?98% (HPLC). Group: Fluorescence/luminescence spectroscopy. | |
| GSK 9311 hydrochloride | GSK9311 is a potent inhibitor of the BRPF bromodomain with pIC50 values of 6.0 and 4.3 for BRPF1 and BRPF2, respectively. GSK 9311 is a negative control for the SGC epigenetic probe GSK6853. Synonyms: N-[2,3-Dihydro-1,3-dimethyl-6-[(2R)-2-methyl-1-piperazinyl]-2-oxo-1H-benzimidazol-5-yl]-N-ethyl-2-methoxybenzamide hydrochloride. Grades: ≥98% by HPLC. CAS No. 1923851-49-3. Molecular formula: C24H31N5O3·HCl. Mole weight: 474. | |
| GSK 962040 | GSK 962040 is a selective motilin receptor agonist with pEC50 value of 7.9. It is effective as a stimulant of human and rabbit gastrointestinal motility. lt represents a new opportunity as a treatment in diabetic gastroparesis. It is discovered as a therapeutic agent for conditions associated with delayed gastric emptying. It is highly selective against motilin receptor over the human ghrelin receptor and hERG. It also has no significant activity against other receptors including 5-HT, adrenergic, dopamine, histamine and adenosine receptors. It is found to enhance the EFS-induced cholinergic contraction and cause a small muscle contraction at high concentration in rabbit isolated gastric antrum. It also induces the contraction of human-isolated stomach preparations at 10μM. It had no significant activity at a range of other receptors (including ghrelin), ion channels and enzymes in vitro. It was preferred because its initial IC50 values at CYP3A4 were significantly higher than our preferred threshold of 10 μM. It induced phasic contractions, the duration of which was dose-related. It strongly facilitated cholinergic activity in the antrum, with lower activity in fundus and small intestine only. It was developed by glaxosmithkline and has been in Cilinic Phase 2. Uses: Gsk 962040 may be used as a treatment in diabetic gastroparesis. Synonyms: GSK-962040; GSK 962040; GSK962040; Camicinal;1-[4-(3-fluoroanilino)piperidin-1-yl]-2-[4-[[(3S)-3-methylpiperazin-1-yl]methyl]phenyl]ethanone. Grades: >98%. CAS No. 923565-21-3. Molecular formula: C25H33FN4O. Mole weight: 424.55. | |
| GSK 962040 hydrochloride | GSK 962040 hydrochloride is the hydrochloride form of GSK 962040, which is a selective motilin receptor agonist with pEC50 value of 7.9. It may be used as a treatment in diabetic gastroparesis. It was developed by glaxosmithkline and has been in Cilinic Phase 2. Uses: Gsk 962040 hydrochloride was developed by glaxosmithkline and has been in cilinic phase 2. Synonyms: Camicinal hydrochloride;GSK-962040 hydrochloride; GSK 962040 hydrochloride; GSK962040 hydrochloride; 2-[4-(3-Fluoroanilino)piperidin-1-yl]-1-[4-[[(3S)-3-methylpiperazin-1-yl]methyl]phenyl]ethanone hydrochloride. Grades: >98%. CAS No. 923565-22-4. Molecular formula: C25H34ClFN4O. Mole weight: 461.02. | |
| GSK963 | GSK963 is a potent and selective inhibitor of RIP1 kinase (RIPK1; IC50=29 nM in FP binding assays). GSK963 displays >10?000-fold selective for RIP1 over 339 other kinases. Synonyms: 2,2-dimethyl-1-[(3S)-3-phenyl-3,4-dihydropyrazol-2-yl]propan-1-one. Grades: ≥98%. CAS No. 2049868-46-2. Molecular formula: C14H18N2O. Mole weight: 230.31. | |
| GSK963 | GSK963 is a chiral, highly potent and selective inhibitor of RIP1 kinase , with an IC 50 of 29 nM. GSK963 is a selective and potent inhibitor of necroptosis in murine and human cells in vitro [1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 2049868-46-2. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg. Product ID: HY-103028A. | |
| GSK983 | ?98% (HPLC). Group: Fluorescence/luminescence spectroscopy. | |
| GSK984 | ?98% (HPLC). Group: Fluorescence/luminescence spectroscopy. | |
| GSK-A1 | GSK-A1 is a selective type III phosphatidylinositol 4-kinase PI4KA (PI4KIII?) inhibitor with a pIC50 of 8.5-9.8. GSK-A1 inhibits PtdIns(4,5)P2 resynthesis with an IC50 of about 3 nM. GSK-A1 potently decreases the levels of PtdIns(4)P with a negligible effect on PtdIns(4,5)P2. GSK-A1 has the potential for anti-hepatitis C virus (HCV) research[1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 1416334-69-4. Pack Sizes: 1 mg; 5 mg; 10 mg; 25 mg. Product ID: HY-125118. | |
| GSK-F1 | PI4KA inhibitor-F1 is a potent PI4KA inhibitor. Synonyms: PI4KA inhibitor-F1. Grades: 98%. CAS No. 1384097-27-1. Molecular formula: C27H18F5N5O4S. Mole weight: 603.5. | |
| GSK J1 | GSK-J1 is a highly potent H3K27 histone demethylase inhibitor with IC50 of 28 nM and 53 nM in cell-free assays for JMJD3 (KDM6B) and UTX (KDM6A), respectively, >10-fold selectivity over other tested demethylases. Synonyms: GSKJ1; GSKJ 1; GSKJ-1. Grades: 98%. CAS No. 1373422-53-7. Molecular formula: C22H23N5O2. Mole weight: 389.45. | |
| GSK-J1 | GSK-J1 is a potent inhibitor of H3K27me3/me2-demethylases JMJD3/KDM6B and UTX/KDM6A , with IC 50 of 60 nM towards KDM6B. Uses: Scientific research. Group: Signaling pathways. CAS No. 1373422-53-7. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-15648. | |
| GSK-J1 | ?98% (HPLC). Group: Fluorescence/luminescence spectroscopy. | |
| GSK-J1 sodium salt | GSK-J1 is a potent and selective inhibitor of the H3K27 histone demethylases JMJD3 and UTX (IC50s = 18 and 56 μM, respectively; IC50 = 60 nM in JMJD3 antibody-based assays). Synonyms: N-[2-(2-pyridinyl)-6-(1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)-4-pyrimidinyl]-β-alanine, monosodium salt. Grades: ≥95%. CAS No. 1797832-71-3. Molecular formula: C22H22N5O2·Na. Mole weight: 411.4. | |
| GSK-J1 Sodium Salt | GSK-J1 Sodium Salt. Group: Biochemicals. Alternative Names: 3-((6-(4,5-Dihydro-1H-benzo[d]azepin-3(2H)-yl)-2-(pyridin-2-yl)pyrimidin-4-yl)amino)propanoate Monosodium Salt. Grades: Highly Purified. Pack Sizes: 5mg. Molecular Formula: C22H22N5NaO2, Molecular Weight: 411.43. US Biological Life Sciences. | Worldwide |
| GSK-J2 | GSK-J2, a benzazepin derivative, has been found to have poor activity as a JMJD3 inhibitor so that could be used in the biological study of GSK-J1 as a negative control. IC50: > 100 μM. Uses: Gsk-j2 has been found to have poor activity as a jmjd3 inhibitor so that could be used in the biological study of gsk-j1 as a negative control. Synonyms: SK-J2; GSK J2; GSKJ2; 1394854-52-4; SCHEMBL15937902; 3705AH. Grades: 98%. CAS No. 1394854-52-4. Molecular formula: C22H23N5O2. Mole weight: 389.45. | |
| GSK-J2 | GSK-J2 is an isomer of GSK-J1 that does not have any specific activity. GSK-J1 is a potent inhibitor of H3K27me3/me2-demethylases JMJD3/KDM6B and UTX/KDM6A. Uses: Scientific research. Group: Signaling pathways. CAS No. 1394854-52-4. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-15648A. | |
| GSK-J2 sodium salt | GSK-J2 is a pyridine regio-isomer of GSK-J1 which poorly inhibits JMJD3 with an IC50 value greater than 100 μM. Synonyms: 3-((6-(4,5-dihydro-1H-benzo[d]azepin-3(2H)-yl)-2-(pyridin-3-yl)pyrimidin-4-yl)amino)propanoic acid, monosodium salt. Grades: ≥90%. CAS No. 2108665-15-0. Molecular formula: C22H23N5O2·Na. Mole weight: 412.4. | |
| GSK-J4 | GSK-J4 Inhibitor. Uses: Scientific use. Product Category: T3100. CAS No. 1373423-53-0. | |
| GSK-J4 | GSK-J4 is a potent dual inhibitor of H3K27me3/me2-demethylases JMJD3/KDM6B and UTX/KDM6A with IC 50 s of 8.6 and 6.6 μM, respectively. GSK-J4 inhibits LPS-induced TNF-α production in human primary macrophages with an IC 50 of 9 μM. GSK J4 is a cell permeable proagent of GSK-J1 [1] [2] [3]. GSK-J4 induces endoplasmic reticulum stress-related apoptosis [4]. Uses: Scientific research. Group: Signaling pathways. CAS No. 1373423-53-0. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-15648B. | |
| GSK-J4 | ?98% (HPLC). Group: Fluorescence/luminescence spectroscopy. | |
| GSK-J4 free base | GSK-J4 is a cell permeable, potent and selective histone demethylase. GSK-J4 is a prodrug of GSK J1, which is the first selective inhibitor of the H3K27 histone demethylase JMJD3 and UTX with IC50 of 60 nM in a cell-free assay and inactive against a panel of demethylases of the JMJ family. GSK-J4 is used to probe the consequences of demethylation of H3K27me3. GSK-J4 inhibits the lipopolysaccharide-induced production of cytokines, including pro-inflammatory tumour necrosis factor (TNF). Uses: Designed for use in research and industrial production. Additional or Alternative Names: GSK-J4 free base; GSK-J-4; GSK-J 4; GSK-J4. Product Category: Others. Appearance: Solid powder. CAS No. 1373423-53-0. Molecular formula: C24H27N5O2. Mole weight: 417.51. Purity: >98%. IUPACName: ethyl 3-((2-(pyridin-2-yl)-6-(1,2,4,5-tetrahydro-3H-benzo[d]azepin-3-yl)pyrimidin-4-yl)amino)propanoate. Canonical SMILES: O=C(OCC)CCNC1=NC(C2=NC=CC=C2)=NC(N3CCC4=CC=CC=C4CC3)=C1. Product ID: ACM1373423530. Alfa Chemistry ISO 9001:2015 Certified. |  |
| GSK J4 HCl | GSK J4 HCl is a cell permeable prodrug of GSK J1, which is the first selective inhibitor of the H3K27 histone demethylase JMJD3 and UTX with IC50 of 60 nM and inactive against a panel of demethylases of the JMJ family. Synonyms: GSK-J4; 1373423-53-0; GSK J4; Ethyl 3-((6-(4,5-dihydro-1H-benzo[d]azepin-3(2H)-yl)-2-(pyridin-2-yl)pyrimidin-4-yl)amino)propanoateethyl 3-[[2-pyridin-2-yl-6-(1,2,4,5-tetrahydro-3-benzazepin-3-yl)pyrimidin-4-yl]amino]propanoate. Grades: >98%. CAS No. 1373423-53-0. Molecular formula: C24H27N5O2.HCl. Mole weight: 453.96. | |
| GSK-J4 hydrochloride | GSK-J4 (hydrochloride) is an ethyl ester derivative of GSK-J1 which blocks demethylation of histone H3K27 with an IC50 value greater than 50 μM in vitro. Synonyms: N-[2-(2-pyridinyl)-6-(1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)-4-pyrimidinyl]-β-alanine, ethyl ester, monohydrochloride. Grades: ≥95%. CAS No. 1797983-09-5. Molecular formula: C24H27N5O2·HCl. Mole weight: 454. | |
| GSK-J4 hydrochloride | GSK-J4 hydrochloride is a potent dual inhibitor of H3K27me3/me2-demethylases JMJD3/KDM6B and UTX/KDM6A with IC 50 s of 8.6 and 6.6 μM, respectively. GSK-J4 hydrochloride inhibits LPS-induced TNF-α production in human primary macrophages with an IC 50 of 9 μM. GSK-J4 hydrochloride is a cell permeable proagent of GSK-J1 [1] [2] [3]. Uses: Scientific research. Group: Signaling pathways. CAS No. 1797983-09-5. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg. Product ID: HY-15648F. | |
| GSK-J4 Hydrochloride | GSK-J4 Hydrochloride. Group: Biochemicals. Alternative Names: Ethyl 3-((6-(4,5-Dihydro-1H-benzo[d]azepin-3(2H)-yl)-2-(pyridin-2-yl)pyrimidin-4-yl)amino)propanoate Monohydrochloride. Grades: Highly Purified. Pack Sizes: 5mg. Molecular Formula: C24H28ClN5O2, Molecular Weight: 453.96. US Biological Life Sciences. | Worldwide |
| GSK-J5 hydrochloride | GSK-J5 is a pyridine regio-isomer of GSK-J4 and it is a weak inhibitor of JMJD3 (IC50 > 100 μM), making it an ideal inactive control molecule for elucidating the functional role of JMJD3 inhibition. Synonyms: N-[2-(3-pyridinyl)-6-(1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)-4-pyrimidinyl]-β-alanine, ethyl ester, monohydrochoride. Grades: ≥95%. CAS No. 1797983-32-4. Molecular formula: C24H27N5O2·HCl. Mole weight: 454. | |
Our database is helping our users find suppliers everyday.
